Quantcast

Latest Angiology Stories

2014-09-18 08:26:01

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA(TM)) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in the online version of The Lancet Oncology. In the trial, known as RAINBOW, the addition of ramucirumab to...

2014-09-16 08:29:26

Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA(®) (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which...

2014-09-15 23:11:17

Center for Vascular Medicine now offers genetic testing as a diagnostic tool in its approach to treating patients with vascular conditions including peripheral artery disease (PAD). Greenbelt, MD (PRWEB) September 15, 2014 With a simple swab of the cheek, the physicians at Center for Vascular Medicine can gain valuable insight to help personalize the treatment for patients with vascular disorders, including peripheral artery disease (PAD). The ideal approach to medicine is preventive...

2014-09-12 08:25:08

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA(TM)) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab...

2014-09-10 20:24:50

LONDON, Sept. 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024https://www.reportbuyer.com/product/2006103/Macular-Degeneration-AMD-and-Other-Retinal-Diseases-World-Drug-Market-2014-2024.html Report DetailsAnalysis of revenues and R&D prospects for those eye drugs - you explore potentialsWhat's the future for treating disorders of the retina? Visiongain's updated...

2014-08-28 12:29:37

BOSTON, Aug. 28, 2014 /PRNewswire/ -- The North American Thrombosis Forum (NATF), a non-profit organization dedicated to increasing public awareness of thrombosis and related cardiovascular diseases, is thrilled to welcome 7 renowned experts in cardiovascular medicine to speak at their Fall educational program, the 8(th) Annual Thrombosis Summit, on Saturday, September 20. The Thrombosis Summit will take place at the beautiful Fairmont Copley Plaza Hotel located in Copley Square in...

2014-08-14 12:27:38

Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that physician-reported patient shares for Regeneron's Eylea, as well as the other major anti-vascular endothelial growth factor (VEGF) agents Genentech/Roche's Avastin and Genentech/Roche's Lucentis, have now stabilized among wet age-related...

2014-08-14 08:28:34

ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20140706/124566 CASI reported a net loss for the second quarter of 2014 of ($1.6 million), or ($0.06) per share. This compares with a net loss of ($1.9 million), or...

2014-08-13 08:26:49

SAN DIEGO, Aug. 13, 2014 /PRNewswire/ -- Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional...

2014-08-11 08:29:48

Varithena® is now available in the US WEST CONSHOHOCKEN, Pa., Aug. 11, 2014 /PRNewswire/ -- BTG International Inc. announces that the first varicose vein patient has been treated with Varithena(®) (polidocanol injectable foam), the only FDA-approved foam for the treatment of incompetent great saphenous veins (GSV), accessory saphenous veins and visible varicosities of the GSV system both above and below the knee. Varithena(®) improves symptoms related to or caused by varicose veins, and...


Latest Angiology Reference Libraries

Heart
2013-01-01 11:25:12

The heart is a part of the circulatory system, and is considered one of the most vital organs of the human body. It is about the size of a fist, has a mass of approximately 300 grams, and its main function is to contract and produce enough pressure to circulate blood throughout the body. The top of the heart where the veins and arteries all connect is called the base. The pointed lower tip of the heart is called the apex. The coronary sulcus is a deep groove that runs horizontally across the...

More Articles (1 articles) »
Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related